P21-dependent G1arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

Abstract

Depsipeptide, FR901228, a novel cyclic peptide inhibitor of histone deacetylase with a unique cytotoxicity profile is currently in phase I clinical trials. Here we demonstrate that, in addition to G2/M arrest, FR901228 causes G1 arrest with Rb hypophosphorylation. In vitro kinase assays demonstrated no direct inhibition of CDK activity, however, an inhibition was observed in CDKs extracted from cells exposed to FR901228. Cyclin D1 protein disappeared between 6 and 12 hours after treatment with FR901228, whereas cyclin E was upregulated. While it did not induce wt p53, FR901228 did induce p21(WAF1/CIP1)in a p53-independent manner. Cell clones lacking p21 were not arrested in G1 phase, but continued DNA synthesis and were arrested in G2/M phase following FR901228 treatment. Finally, FR901228 blunted ERK-2/MAPK activation by EGF whereas early signal transduction events remained intact since overall cellular tyrosine phosphorylation after EGF stimulation was unaffected. Thus, FR901228, while not directly inhibiting kinase activity, causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. In contrast to the G1 arrest, the G2/M arrest is p21-independent, but is associated with significant cytotoxicity.

References 44

1. 1.

   Aktas H., Cai H., Cooper G. M. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol. 1997;17(7):3850-3857.

   Not in our library10.1128/mcb.17.7.3850

2. 2.

   Archer S. Y., Meng S., Shei A., Hodin R. A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A. 1998;95(12):6791-6796.

   Not in our library10.1073/pnas.95.12.6791

3. 3.

   Blagosklonny M. V. A node between proliferation, apoptosis, and growth arrest. Bioessays. 1999;21(8):704-709.

   Not in our library10.1002/(sici)1521-1878(199908)21:8<704::aid-bies10>3.0.co;2-5

4. 4.

   Botz J., Zerfass-Thome K., Spitkovsky D., Delius H., Vogt B., Eilers M., Hatzigeorgiou A., Jansen-Dürr P. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol. 1996;16(7):3401-3409.

   Not in our library10.1128/mcb.16.7.3401

5. 5.

   Brehm A., Miska E. A., McCance D. J., Reid J. L., Bannister A. J., Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 1998;391(6667):597-601.

   Not in our library10.1038/35404

6. 6.

   Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J. P., Sedivy J. M., Kinzler K. W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282(5393):1497-1501.

   Not in our library10.1126/science.282.5393.1497

7. 7.

   Campisi J., Medrano E. E., Morreo G., Pardee A. B. Restriction point control of cell growth by a labile protein: evidence for increased stability in transformed cells. Proc Natl Acad Sci U S A. 1982;79(2):436-440.

   Not in our library10.1073/pnas.79.2.436

8. 8.

   Candido E. P., Reeves R., Davie J. R. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 1978;14(1):105-113.

   Not in our library10.1016/0092-8674(78)90305-7

9. 9.

   Chen X., Bargonetti J., Prives C. p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res. 1995;55(19):4257-4263.

   Not in our library

10. 10.

    DeGregori J., Leone G., Ohtani K., Miron A., Nevins J. R. E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev. 1995;9(23):2873-2887.

    Not in our library10.1101/gad.9.23.2873

11. 11.

    Grignani F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., Fanelli M., Ruthardt M., Ferrara F. F., Zamir I. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998;391(6669):815-818.

    Not in our library10.1038/35901

12. 12.

    Hunter T. Oncoprotein networks. Cell. 1997;88(3):333-346.

    Not in our library10.1016/s0092-8674(00)81872-3

13. 13.

    Jacks T., Weinberg R. A. Cell-cycle control and its watchman. Nature. 1996;381(6584):643-644.

    Not in our library10.1038/381643a0

14. 14.

    Johnson D. G., Schwarz J. K., Cress W. D., Nevins J. R. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993;365(6444):349-352.

    Not in our library10.1038/365349a0

15. 15.

    Juan G., Li X., Darzynkiewicz Z. Phosphorylation of retinoblastoma protein assayed in individual HL-60 cells during their proliferation and differentiation. Exp Cell Res. 1998;244(1):83-92.

    Not in our library10.1006/excr.1998.4165

16. 16.

    Kim Y. B., Lee K. H., Sugita K., Yoshida M., Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene. 1999;18(15):2461-2470.

    Not in our library10.1038/sj.onc.1202564

17. 17.

    Kosugi H., Towatari M., Hatano S., Kitamura K., Kiyoi H., Kinoshita T., Tanimoto M., Murate T., Kawashima K., Saito H. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia. 1999;13(9):1316-1324.

    Not in our library10.1038/sj.leu.2401508

18. 18.

    Lee J. S., Paull K., Alvarez M., Hose C., Monks A., Grever M., Fojo A. T., Bates S. E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol. 1994;46(4):627-638.

    Not in our library

19. 19.

    Lin R. J., Nagy L., Inoue S., Shao W., Miller W. H., Evans R. M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391(6669):811-814.

    Not in our library10.1038/35895

20. 20.

    Luo R. X., Postigo A. A., Dean D. C. Rb interacts with histone deacetylase to repress transcription. Cell. 1998;92(4):463-473.

    Not in our library10.1016/s0092-8674(00)80940-x

21. 21.

    Magnaghi-Jaulin L., Groisman R., Naguibneva I., Robin P., Lorain S., Le Villain J. P., Troalen F., Trouche D., Harel-Bellan A. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature. 1998;391(6667):601-605.

    Not in our library10.1038/35410

22. 22.

    Nakajima H., Kim Y. B., Terano H., Yoshida M., Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res. 1998;241(1):126-133.

    Not in our library10.1006/excr.1998.4027

23. 23.

    Nevins J. R. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ. 1998;9(8):585-593.

    Not in our library

24. 24.

    Oswald F., Lovec H., Möröy T., Lipp M. E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. Oncogene. 1994;9(7):2029-2036.

    Not in our library

25. 25.

    Pardee A. B. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A. 1974;71(4):1286-1290.

    Not in our library10.1073/pnas.71.4.1286

26. 26.

    Polyak K., Waldman T., He T. C., Kinzler K. W., Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 1996;10(15):1945-1952.

    Not in our library10.1101/gad.10.15.1945

27. 27.

    Rajgolikar G., Chan K. K., Wang H. C. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res Treat. 1998;51(1):29-38.

    Not in our library10.1023/a:1006091014092

28. 28.

    Richon V. M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R. A., Marks P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998;95(6):3003-3007.

    Not in our library10.1073/pnas.95.6.3003

29. 29.

    Sherr C. J. Cancer cell cycles. Science. 1996;274(5293):1672-1677.

    Not in our library10.1126/science.274.5293.1672

30. 30.

    Soule H. D., Maloney T. M., Wolman S. R., Peterson W. D., Brenz R., McGrath C. M., Russo J., Pauley R. J., Jones R. F., Brooks S. C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990;50(18):6075-6086.

    Not in our library

31. 31.

    Sowa Y., Orita T., Minamikawa S., Nakano K., Mizuno T., Nomura H., Sakai T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun. 1997;241(1):142-150.

    Not in our library10.1006/bbrc.1997.7786

32. 32.

    Stewart Z. A., Leach S. D., Pietenpol J. A. p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol Cell Biol. 1999;19(1):205-215.

    Not in our library10.1128/mcb.19.1.205

33. 33.

    Ueda H., Manda T., Matsumoto S., Mukumoto S., Nishigaki F., Kawamura I., Shimomura K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo). 1994;47(3):315-323.

    Not in our library10.7164/antibiotics.47.315

34. 34.

    Ueda H., Nakajima H., Hori Y., Fujita T., Nishimura M., Goto T., Okuhara M. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994;47(3):301-310.

    Not in our library10.7164/antibiotics.47.301

35. 35.

    Ueda H., Nakajima H., Hori Y., Goto T., Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem. 1994;58(9):1579-1583.

    Not in our library10.1271/bbb.58.1579

36. 36.

    Vaziri C., Stice L., Faller D. V. Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ. 1998;9(6):465-474.

    Not in our library

37. 37.

    Waldman T., Kinzler K. W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995;55(22):5187-5190.

    Not in our library

38. 38.

    Wang R., Brunner T., Zhang L., Shi Y. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene. 1998;17(12):1503-1508.

    Not in our library10.1038/sj.onc.1202059

39. 39.

    Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell. 1995;81(3):323-330.

    Not in our library10.1016/0092-8674(95)90385-2

40. 40.

    Wosikowski K., Regis J. T., Robey R. W., Alvarez M., Buters J. T., Gudas J. M., Bates S. E. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ. 1995;6(11):1395-1403.

    Not in our library

Cited by papers we hold 3

• Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors · 2020
  Not checked
• Histone Deacetylase Inhibitors as Anticancer Drugs · 2017
  No notice
• Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents · 2015
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.